Esperion Therapeutics' P2P Acquisition

Esperion Therapeutics raised a round of funding on December 22, 2003. Investors include Pfizer.

Esperion Therapeutics discovers and develops therapies for the treatment of cardiometabolic diseases. The company's lead product candidate, ETC-1002, is an AMP kinase activator and ATP citrate lyase i…

Articles about Esperion Therapeutics' P2P Acquisition: